This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudolph, P. Articles by Christophers, E. Search for Related Content PubMed PubMed Citation Articles by Rudolph, P. Articles by Christophers, E.

American Journal of Pathology, Vol 147, 1615-1625, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions

P Rudolph, T Lappe, C Schubert, D Schmidt, RM Parwaresch and E Christophers
Institute of Pathology, Kiel, Germany.

The aim of this study was to gain a thorough insight into the proliferative activity of benign and malignant melanocytic tumors. A total of 314 cases were examined by immunohistochemistry on paraffin- embedded material. The growth fraction was assessed by means of two monoclonal antibodies, Ki-S1 and Ki-S5, which react with two different proliferation-specific nuclear antigens. Additionally, HMB-45 was used as a marker of melanocytic activation. Statistically significant differences (P < 0.01) in the proliferation rates were found between common acquired nevi, Spitz's/Reed's nevi, primary cutaneous melanomas, and metastatic melanomas, whereas dysplastic nevi were hardly distinct from other nevi of the compound type. In melanoma, the growth fraction correlated well with the tumor stage but poorly with HMB-45 expression and mitotic count. Along with tumor progression, an increasing heterogeneity of proliferation indices was observed. Our results provide no evidence for a progression from dysplastic nevi into melanoma. They indicate that the assessment of the proliferative activity may be of considerable diagnostic help in cases of uncertain histology and that it might contribute to an alternative concept for the classification of melanocytic tumors.

This article has been cited by other articles:

				C F Lindboe and S H Torp Comparison of Ki-67 equivalent antibodies J. Clin. Pathol., June 1, 2002; 55(6): 467 - 471. [Abstract] [Full Text] [PDF]

				J. A. Carlson, X. C. Mu, A. Slominski, K. Weismann, A. N. Crowson, J. Malfetano, V. G. Prieto, and M. C. Mihm Jr Melanocytic Proliferations Associated With Lichen Sclerosus Arch Dermatol, January 1, 2002; 138(1): 77 - 87. [Abstract] [Full Text] [PDF]

				P. Rudolph, C. Schubert, S. Tamm, K. Heidorn, A. Hauschild, I. Michalska, S. Majewski, G. Krupp, S. Jablonska, and R. Parwaresch Telomerase Activity in Melanocytic Lesions : A Potential Marker of Tumor Biology Am. J. Pathol., April 1, 2000; 156(4): 1425 - 1432. [Abstract] [Full Text] [PDF]

				P. Rudolph, U. Kellner, D. Schmidt, V. Kirchner, A. Talerman, D. Harms, and R. Parwaresch Ki-A10, a Germ Cell Nuclear Antigen Retained in a Subset of Germ Cell-Derived Tumors Am. J. Pathol., March 1, 1999; 154(3): 795 - 803. [Abstract] [Full Text] [PDF]

				P. Rudolph, P. Alm, H.-J. Heidebrecht, H. Bolte, V. Ratjen, B. Baldetorp, M. Ferno, H. Olsson, and R. Parwaresch Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 271 - 278. [Abstract] [Full Text] [PDF]

				J. L. Arbiser Melanoma: Lessons From Metastases Arch Dermatol, August 1, 1998; 134(8): 1027 - 1028. [Full Text] [PDF]

				U. Kellner, H.-J. Heidebrecht, P. Rudolph, H. Biersack, F. Buck, T. Dakowski, H.-H. Wacker, M. Domanowski, A. Seidel, O. Westergaard, et al. Detection of Human Topoisomerase II{alpha} in Cell Lines and Tissues: Characterization of Five Novel Monoclonal Antibodies J. Histochem. Cytochem., February 1, 1997; 45(2): 251 - 264. [Abstract] [Full Text] [PDF]